2311 results about "Acid derivative" patented technology

The invention provides a lubricating composition containing an oil of lubricating viscosity, an oil soluble molybdenum compound, and an ashless antiwear agent. The invention further provides for a new antioxidant. The lubricating composition is suitable for lubricating an internal combustion engine.

Methods and compositions for producing fatty acid derivatives, for example, fatty esters, and commercial fuel compositions comprising fatty acid derivatives are described.

A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or 0-acyl isourea, or both N-acylurea and 0-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid.

The present invention provides a method of producing a fluoropolymer, wherein polymerization using a carboxylate ester bond-containing carboxylic acid derivative as a surfactant in an aqueous medium to give the fluoropolymer is conducted, the above carboxylate ester bond-containing carboxylic acid derivative has a carboxylate ester bond and —COOM (M representing H, NH₄, Li, Na or K), the above carboxylate ester bond may optionally be substituted by fluorine atom.

The invention belongs to the technical field of concrete additives in building materials. The high water reduction high collapse protection type polycarboxylate high-performance water reducer mainly comprises the following monomer components: unsaturated methyl vinyl polyoxyethylene ether (A), a chain transfer agent (B), a mixture (C) of one or more of unsaturated acid and unsaturated acid derivatives, an oxidant (D) and a reducing agent (E), wherein the molar ratio A: B: C: D: E of the monomers is 1:0.01-0.5:2-8:0.08-0.5:0.02-0.3. The high water reduction high collapse protection type polycarboxylate high-performance water reducer is prepared by regulating the polymer mass concentration to between 20 and 40 percent by using water, and polymerizing a redox initiator system at normal temperature. The water reducer has the advantages of low doping amount, high water reducing ratio, excellent slump retaining capacity, and high cement adaptability, and the technology has the advantages of no need of extra heat source, implementation at normal temperature, low equipment investment, low cost and suitability for large area popularization and application.

The present invention relates to sustained-release pharmaceutical compositions for ionic pharmaceutically active substances (excluding ionic prostanoic acid derivatives) containing ionic compounds having opposite charges to those of the active substances and increasing hydrophobicity of the active substances. More specifically, the invention relates to sustained-release pharmaceutical compositions comprising the ionic pharmaceutically active substances and the ionic compounds having opposite charges to those of the active substances and increasing hydrophobicity of the active substances that contain hydrophobic groups in the molecule thereof. The pharmaceutical composition of the invention can exhibit excellent sustained release effect of the active substance, irrespective of water solubility possessed by the ionic pharmaceutically active substances.

According to a first aspect the invention relates to the use of fumaric acid derivatives selected from the group consisting of dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, monoamido fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these compounds and mixtures thereof for preparing a drug for the treatment or prevention of cardiac insufficiency, in particular left ventricular insufficiency, myocardial infarction and angina pectoris. According to a second aspect the invention relates to the use of fumaric acid derivatives, selected from the group consisting of dialkyl fumarates, monoalkyl hydrogen fumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, monoamido fumaric acid salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these compounds and mixtures thereof for preparing a drug for the treatment of asthma and chronic obstructive pulmonary diseases, especially asthma caused by allergies, infections, analgesics, job conditions or physical effort, mixed forms of asthma, or asthma cardiale.

It is intended to provide a bicyclic γ-amino acid derivative having excellent activity as an α₂δ ligand. The present invention provides a compound represented by the general formula (I):

wherein R¹, R², R^2′, R⁴, R⁵, R⁶, R⁷, R⁸, and R^8′ are a hydrogen atom or the like; and R³ is a hydrogen atom, a halogen atom, a C1-C6 alkyl group, or the like.

The invention provides a black composite reactive dye having three primary color constituents comprising, green disazo dye employing ethylene sulfone series arylamine or aniline derivative as diazo component and H acid as coupling component, one ore more red disazo dyes employing sulfoalkyl J acid or carboxymethyl J acid derivatives as coupling components, one ore more yellow bisazo or polyazo dyes employing sulfochlorinated 3,5-diaminobenzoic acid or sulfoalkyl derivatives as coupling components. The dye can be applied to intermittent and continuous dyeing for cellulose fiber, protein fiber, poly nylon and their fiber mixed fabrics.

The present invention provides 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid compounds and their addition salts, and processes for preparing them, which have antagonism against excitatory amino acid receptors, in particular, an AMPA receptor. The 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid compounds and their addition salts of the present invention are represented by formula (1)wherein Q, R, R1 and R2 are as described in the specification.

Compounds of Formula 1, Formula 2 or Formula 3 where X is O, S, or (CR1R1)n where n is 0, 1 or 2; Y is a bivalent radical having Formula 4 or Formula 5 where o is an integer from 1 to 4 or Y is a bivalent aryl or 5 or 6 membered heteroaryl radical having 1 to 3 heteroatoms selected from N, S and O, said aryl or heteroaryl groups being unsubstituted, or substituted with 1 to 3 C1-6 alkyl or with 1 to 3 C1-6 fluoroalkyl groups; and the remaining symbols have the meaning described in the specification, have RXR selective retinoid agonist-like activity.

The invention provides a unit formulation which comprises a 2-hydroxy-5-phenylazobenzoic acid derivative which is particularly sodium balsalazide dihydrate which formulation has a density of at least 0.9 mg/mm3 and its use in the treatment of gastrointestinal diseases.

A compound of the formula (1): FSO2CFXCF2O(CFXCF2O)nCF-(CF2Y)COF in which X is a fluorine atom, a chlorine atom or a trifluoromethyl group, Y is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, and n is a number of 0 to 5, preferably 0, 1 or 2, is converted to a compound of the formula (2): MOSO2CFXCF2O(CFXCF2O)2CF(CF2Y)COOM1 in which X, Y and n are the same as defined above, and M and M1 independently represent an alkali metal atom or an alkaline earth metal atom, and then a compound of the formula (2) is pyrolyzed at a temperature of 150 to 250° C. to obtain a compound of the formula (3): ASO2CFXCF2O(CFXCF2O)nCF=CF2 in which A is MO-, a hydroxyl group or a fluorine atom, and X and n are the same as defined above.

The present invention provides methods and compositions for preparing 4-substituted 3-hydroxybutyric acid derivatives by halohydrin dehalogenase-catalyzed conversion of 4-halo-3-hydroxybutyric acid derivatives. The present invention further provides methods and compositions for preparing 4-halo-3-hydroxybutyric acid derivatives by ketoreductase-catalyzed conversion of 4-halo-3-ketobutyric acid derivatives.

The present invention provides methods and compositions for preparing 4-substituted 3-hydroxybutyric acid derivatives by halohydrin dehalogenase-catalyzed conversion of 4-halo-3-hydroxybutyric acid derivatives. The present invention further provides methods and compositions for preparing 4-halo-3-hydroxybutyric acid derivatives by ketoreductase-catalyzed conversion of 4-halo-3-ketobutyric acid derivatives The present invention also provides methods and compositions for preparing vicinal cyano, hydroxyl substituted carboxylic acid esters.

The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

The invention discloses a hyaluronic acid derivative and a preparation method thereof. The preparation method comprises the following steps: carrying out hybrid reaction on hyaluronic acid/salt and anhydride in an anhydrous solvent, and precipitating, separating and purifying the product, so that the hyaluronic acid derivative with cross-linkable performance is obtained. The preparation method is simple in process, the reaction degree can be controlled through controlling the reaction parameter, and the product obtained through the method is stable in property, and can be kept for a long time; in addition, the obtained hyaluronic acid derivative with the cross-linkable performance can be used for preparing hyaluronic acid hydrogel under a mild condition, has an excellent biocompatibility, and can be applied to the carrier material of a bio-active substance, a tissue engineering scaffold material and a soft tissue filling material.

Glutamic acid derivatives, in particular monatin, may be conveniently prepared by alkylating a 4-protected hydroxyl pyroglutamic acid derivative with an alkylating agent to prepare a 4-protected hydroxyl-4-alkylglutamic acid derivative, followed by the steps of hydrolysis and deprotection. The 4-protected hydroxyl pyroglutamic acid derivative is easy to produce from hydroxyproline. The 4-protected hydroxyl pyroglutamic acid derivative is particularly suitable for use in the efficient manufacture of monatin of high optical purity, since it can be alkylated selectively at the 4-position and stereoselectively and after its alkylation, it can easily be converted to a glutamic acid derivative.

The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.